Purchase this article with an account.
C. B. Chambers, T. H. Mahmoud; Role of Fluorescein Angiography and Optical Coherence Tomography to Guide Treatment With Anti-VEGF Therapy in Patients With Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2008;49(13):271.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the frequency of fluorescein angiographic (FA) leakage and optical coherence tomography (OCT) changes (subretinal fluid, macular edema) in patients with neovascular AMD on anti-VEGF therapy (Pegaptanib, Bevacizumab, Ranibizumab).
A retrospective interventional study was conducted of patients diagnosed with NVAMD on anti-VEGF therapy. We included only visits in which both FA, OCT and an injection were administered. Exclusion criteria included presence of disciform scars, CNV secondary to causes other than AMD, and co-existing diseases causing macular pathology. Images were reviewed to determine evidence of FA leakage and OCT changes.
Fifty-three visits were identified to have both FA and OCT images available for interpretation. FA leakage was seen in 50 of 53 injections (94.3 %). OCT changes were seen in 27 of 53 injections (50.9 %). All of the eyes with OCT changes showed evidence of FA leakage, while eyes with no OCT changes showed FA leakage in 23 of 53 injections (43.4%).
This PDF is available to Subscribers Only